Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Meth ruling goes to pharma

This article was originally published in The Tan Sheet

Executive Summary

Twenty Arkansas counties failed to show pharmaceutical firms were responsible for the "societal effects of the methamphetamine epidemic," according to the Jan. 5 decision by the U.S. Court of Appeals for the Eighth Circuit to dismiss the counties' complaint. The counties alleged that the companies opposed regulatory efforts in order to reap profits from the sale of OTC cough/cold products with ephedrine or pseudoephedrine. Arkansas, which ordered behind-the-counter sales of PSE-containing products before the federal Combat Meth Act of 2006 was enacted, instituted e-tracking for PSE product sales in 2008 (1"The Tan Sheet" June 9, 2008, In Brief)

You may also be interested in...

Arkansas e-tracking PSE

Sales of OTC products containing pseudoephedrine across Arkansas are being tracked on a real-time statewide electronic logbook, state Attorney General Dustin McDaniel says June 4. Arkansas was among the states that imposed behind-the-counter sales of PSE-containing OTC products before the federal Combat Methamphetamine Epidemic Act of 2006 required all states to implement sales restrictions as least as stringent (1"The Tan Sheet" July 3, 2006, p. 7). However, Arkansas found paper logbooks ineffective against meth makers who stock up on PSE drugs by visiting multiple retailers. Federal legislation, S. 1276, to fund electronic logs for states has stalled in the Senate, but Arkansas and other states - including Iowa, Oklahoma and Tennessee - have implemented their own tracking systems (2"The Tan Sheet" March 19, 2007, p. 11)...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts